Nucleate UK (LinkedIn) · May 2026
Founder-story article describing Nanograb's path from Imperial College London into a startup, highlighting the early decisions behind the company.
AI-generated binders for targeted drug delivery
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Nanograb is a 2023 London-based, Y Combinator S23 biotechnology company building AI-designed multivalent nanoparticles and peptide-binder systems for cell-selective, non-viral gene delivery.
Primary product
AI-designed multivalent nanoparticles for targeted non-viral gene therapy / cell-selective drug delivery
Founded
2023
Headquarters
London, England, United Kingdom
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Computational drug discovery and nanomedicine
Offices
London, England, United Kingdom
Open Positions
0 jobs at Nanograb
No open positions
Check back later for new openings